Literature DB >> 22678151

The safety of peanut oral immunotherapy in peanut-allergic subjects in a single-center trial.

G P Yu1, B Weldon, S Neale-May, K C Nadeau.   

Abstract

BACKGROUND: Peanut allergy is the leading cause of food-related anaphylaxis, and accidental exposures are common. Oral immunotherapy (OIT) has been posited as a potential treatment.
METHODS: Patients aged 3-65 years with peanut-specific IgE ≥7 kU/l and/or a positive skin prick test with a history of an allergic reaction to peanut were recruited to undergo an OIT protocol. All adverse reactions were recorded by research staff or patients in real time.
RESULTS: Twenty-four patients received 6,662 doses. Symptoms were mostly mild (84%), and only 3 severe gastrointestinal reactions required the administration of epinephrine. Abdominal pain was the most common reaction, followed by oropharyngeal and lip pruritus. Respiratory symptoms were rare.
CONCLUSIONS: In this trial of OIT in adults and children, most reactions were mild.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22678151      PMCID: PMC3505766          DOI: 10.1159/000336391

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  13 in total

1.  Office-based oral immunotherapy for food allergy is safe and effective.

Authors:  Richard L Wasserman; Robert W Sugerman; Nana Mireku-Akomeah; Lyndon Mansfield; James W Baker
Journal:  J Allergy Clin Immunol       Date:  2010-10-30       Impact factor: 10.793

2.  Frequency of US emergency department visits for food-related acute allergic reactions.

Authors:  Sunday Clark; Janice Espinola; Susan A Rudders; Aleena Banerji; Carlos A Camargo
Journal:  J Allergy Clin Immunol       Date:  2010-12-16       Impact factor: 10.793

3.  Peanut oral immunotherapy is not ready for clinical use.

Authors:  Ananth Thyagarajan; Pooja Varshney; Stacie M Jones; Scott Sicherer; Robert Wood; Brian P Vickery; Hugh Sampson; A Wesley Burks
Journal:  J Allergy Clin Immunol       Date:  2010-07       Impact factor: 10.793

Review 4.  Double-blind, placebo-controlled food challenge (DBPCFC) as an office procedure: a manual.

Authors:  S A Bock; H A Sampson; F M Atkins; R S Zeiger; S Lehrer; M Sachs; R K Bush; D D Metcalfe
Journal:  J Allergy Clin Immunol       Date:  1988-12       Impact factor: 10.793

Review 5.  Epidemiology of food allergy.

Authors:  Scott H Sicherer
Journal:  J Allergy Clin Immunol       Date:  2011-01-13       Impact factor: 10.793

6.  Oral peanut immunotherapy in children with peanut anaphylaxis.

Authors:  Katharina Blumchen; Helen Ulbricht; Ute Staden; Kerstin Dobberstein; John Beschorner; Lucila Camargo Lopes de Oliveira; Wayne G Shreffler; Hugh A Sampson; Bodo Niggemann; Ulrich Wahn; Kirsten Beyer
Journal:  J Allergy Clin Immunol       Date:  2010-06-12       Impact factor: 10.793

7.  A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response.

Authors:  Pooja Varshney; Stacie M Jones; Amy M Scurlock; Tamara T Perry; Alex Kemper; Pamela Steele; Anne Hiegel; Janet Kamilaris; Suzanne Carlisle; Xiaohong Yue; Mike Kulis; Laurent Pons; Brian Vickery; A Wesley Burks
Journal:  J Allergy Clin Immunol       Date:  2011-03       Impact factor: 10.793

8.  Clinical efficacy and immune regulation with peanut oral immunotherapy.

Authors:  Stacie M Jones; Laurent Pons; Joseph L Roberts; Amy M Scurlock; Tamara T Perry; Mike Kulis; Wayne G Shreffler; Pamela Steele; Karen A Henry; Margaret Adair; James M Francis; Stephen Durham; Brian P Vickery; Xiaoping Zhong; A Wesley Burks
Journal:  J Allergy Clin Immunol       Date:  2009-07-03       Impact factor: 10.793

9.  Safety of a peanut oral immunotherapy protocol in children with peanut allergy.

Authors:  Alison M Hofmann; Amy M Scurlock; Stacie M Jones; Kricia P Palmer; Yuliya Lokhnygina; Pamela H Steele; Janet Kamilaris; A Wesley Burks
Journal:  J Allergy Clin Immunol       Date:  2009-05-27       Impact factor: 10.793

10.  Food allergy among children in the United States.

Authors:  Amy M Branum; Susan L Lukacs
Journal:  Pediatrics       Date:  2009-11-16       Impact factor: 7.124

View more
  14 in total

1.  A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients.

Authors:  Lynda C Schneider; Rima Rachid; Jennifer LeBovidge; Emily Blood; Mudita Mittal; Dale T Umetsu
Journal:  J Allergy Clin Immunol       Date:  2013-10-28       Impact factor: 10.793

Review 2.  Current opinion and review on peanut oral immunotherapy.

Authors:  Sharon Deol; J Andrew Bird
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 3.  Immunotherapy in allergy and cellular tests: state of art.

Authors:  Salvatore Chirumbolo
Journal:  Hum Vaccin Immunother       Date:  2014-05-02       Impact factor: 3.452

4.  Novel baseline predictors of adverse events during oral immunotherapy in children with peanut allergy.

Authors:  Yamini V Virkud; A Wesley Burks; Pamela H Steele; Lloyd J Edwards; Jelena P Berglund; Stacie M Jones; Amy M Scurlock; Tamara T Perry; Robert D Pesek; Brian P Vickery
Journal:  J Allergy Clin Immunol       Date:  2016-09-05       Impact factor: 10.793

Review 5.  Emerging therapies for food allergy.

Authors:  Corinne A Keet; Robert A Wood
Journal:  J Clin Invest       Date:  2014-05-01       Impact factor: 14.808

Review 6.  Oral immunotherapy for the treatment of food allergy.

Authors:  Philippe Begin; R Sharon Chinthrajah; Kari C Nadeau
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 7.  Food-Induced Anaphylaxis: an Update.

Authors:  Christopher P Parrish; Heidi Kim
Journal:  Curr Allergy Asthma Rep       Date:  2018-06-14       Impact factor: 4.806

8.  Transcriptional changes in peanut-specific CD4+ T cells over the course of oral immunotherapy.

Authors:  Weiqi Wang; Shu-Chen Lyu; Xuhuai Ji; Sheena Gupta; Monali Manohar; Gopal K R Dhondalay; Sharon Chinthrajah; Sandra Andorf; Scott D Boyd; Robert Tibshirani; Stephen J Galli; Kari C Nadeau; Holden T Maecker
Journal:  Clin Immunol       Date:  2020-08-09       Impact factor: 3.969

9.  Safety and feasibility of oral immunotherapy to multiple allergens for food allergy.

Authors:  Philippe Bégin; Lisa C Winterroth; Tina Dominguez; Shruti P Wilson; Liane Bacal; Anjuli Mehrotra; Bethany Kausch; Anthony Trela; Elisabeth Hoyte; Gerri O'Riordan; Scott Seki; Alanna Blakemore; Margie Woch; Robert G Hamilton; Kari C Nadeau
Journal:  Allergy Asthma Clin Immunol       Date:  2014-01-15       Impact factor: 3.406

10.  Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab.

Authors:  Philippe Bégin; Tina Dominguez; Shruti P Wilson; Liane Bacal; Anjuli Mehrotra; Bethany Kausch; Anthony Trela; Morvarid Tavassoli; Elisabeth Hoyte; Gerri O'Riordan; Alanna Blakemore; Scott Seki; Robert G Hamilton; Kari C Nadeau
Journal:  Allergy Asthma Clin Immunol       Date:  2014-02-20       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.